AURA

Aura Biosciences, Inc. (AURA) 10Y Growth Potential Analysis (2026)

Invetso Score: 4/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Growth

Revenue growth is not evidenced in the provided metrics, with revenue per share at 0 and margins at 0 across the board.

Negative profitability and cash flow metrics suggest the business is not yet demonstrating durable growth economics.

Profitability

TTM returns are deeply negative, including ROA at -37.6%, ROE at -73.2%, and ROIC at -41.6%.

Operating, EBITDA, and net profit margins are all 0, indicating no current operating profitability.

Financial Health

Liquidity is very strong with a current ratio of 16.8x and quick ratio of 16.8x.

Balance sheet leverage is low, with debt-to-equity at 0.05x and debt-to-assets at 0.05x, while cash per share is 3.41.

Shareholder Returns

No dividend is being paid, with dividend yield and payout ratio both at 0.

Negative earnings and free cash flow imply limited near-term capacity for shareholder-friendly capital returns.

Valuation

Valuation appears asset-backed rather than earnings-backed, with price-to-book at 2.34x and price-to-fair-value at 2.34x.

Negative earnings and cash flow make earnings-based multiples less meaningful, but the low enterprise value relative to the balance sheet supports a middling valuation view.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Aura Biosciences, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →